VB-111 is a targeted anti-cancer biologic agent that is positioned to potentially treat a wide range of solid tumors indications.

OVAL, our Phase 3 study of VB-111 in platinum-resistant Ovarian Cancer was launched in December 2017. The OVAL study is comparing VB-111 therapy in combination with paclitaxel, to paclitaxel alone.